INZY Research and Charts

INZY - Inozyme Pharma Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-06-30)

Last 4.00	Change ⇑ +0.01 (+0.25%)	Volume 1,457,159
	Open 4.00	High 4.00	Low 3.99

8EMA (Daily) 3.99	40EMA (Daily) 3.35	50EMA (Daily) 3.14	STO (Daily) 80.000	MACD Hist (Daily) -0.143
8EMA (Weekly) 3.608	40EMA (Weekly) 2.95	50EMA (Weekly) 3.08	STO (Weekly) 99.939	MACD Hist (Weekly) 0.609


Company Profile
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.